AU2022314207A1 - Ulodesine salt - Google Patents

Ulodesine salt Download PDF

Info

Publication number
AU2022314207A1
AU2022314207A1 AU2022314207A AU2022314207A AU2022314207A1 AU 2022314207 A1 AU2022314207 A1 AU 2022314207A1 AU 2022314207 A AU2022314207 A AU 2022314207A AU 2022314207 A AU2022314207 A AU 2022314207A AU 2022314207 A1 AU2022314207 A1 AU 2022314207A1
Authority
AU
Australia
Prior art keywords
salt
ulodesine
hemi
glutarate
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022314207A
Other languages
English (en)
Inventor
Xianfeng CHAI
Yao HAN
Juan Liu
Qiuhong LUO
Thomas MEHRLING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laevoroc Immunology Ag
Original Assignee
Laevoroc Immunology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laevoroc Immunology Ag filed Critical Laevoroc Immunology Ag
Publication of AU2022314207A1 publication Critical patent/AU2022314207A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2022314207A 2021-07-20 2022-07-20 Ulodesine salt Pending AU2022314207A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2110403.9A GB202110403D0 (en) 2021-07-20 2021-07-20 Ulodesine Salt
GB2110403.9 2021-07-20
PCT/EP2022/070369 WO2023001893A1 (en) 2021-07-20 2022-07-20 Ulodesine salt

Publications (1)

Publication Number Publication Date
AU2022314207A1 true AU2022314207A1 (en) 2024-01-18

Family

ID=77443478

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022314207A Pending AU2022314207A1 (en) 2021-07-20 2022-07-20 Ulodesine salt

Country Status (9)

Country Link
EP (1) EP4373579A1 (enExample)
JP (1) JP2024525254A (enExample)
KR (1) KR20240038017A (enExample)
CN (1) CN117897383A (enExample)
AU (1) AU2022314207A1 (enExample)
CA (1) CA3226849A1 (enExample)
GB (1) GB202110403D0 (enExample)
MX (1) MX2024000936A (enExample)
WO (1) WO2023001893A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218782D0 (en) 2022-12-13 2023-01-25 Mehrling Thomas Purine nucleoside phosphorylase inhibitor for metabolic syndrome
WO2025250900A1 (en) * 2024-05-30 2025-12-04 Caamtech, Inc. 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553839B2 (en) 2002-08-21 2009-06-30 Industrial Research Limited 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
MX2011009928A (es) * 2009-03-24 2012-03-16 Biocryst Pharm Inc Sales farmaceuticas utiles de 7[(3r, 4r)-3-hidroxi-4-hidroximetil- pirrolidin-1-ilmetil]-3,5-dihidro-pirrol[3,2-d]pirimidin-4-ona.

Also Published As

Publication number Publication date
KR20240038017A (ko) 2024-03-22
GB202110403D0 (en) 2021-09-01
WO2023001893A4 (en) 2023-03-30
CA3226849A1 (en) 2023-01-26
MX2024000936A (es) 2024-06-19
JP2024525254A (ja) 2024-07-11
CN117897383A (zh) 2024-04-16
WO2023001893A1 (en) 2023-01-26
EP4373579A1 (en) 2024-05-29

Similar Documents

Publication Publication Date Title
US8501753B2 (en) Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-D] pyrimidin-4-one
US20180155291A1 (en) New crystal form of lenvatinib methanesulfonate salt and preparation method thereof
CA3056133A1 (en) Crystal forms of amino lipids
US20100256212A1 (en) Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
KR20140075703A (ko) 프리도피딘 하이드로클로라이드의 다형 형태
EP4373579A1 (en) Ulodesine salt
CN112142679A (zh) 一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法
CN114072406B (zh) Flna-结合化合物及其盐酸盐的固体多晶型物
US20240391933A1 (en) Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
US12202834B2 (en) Solid state forms of oclacitinib maleate
US20260103462A1 (en) Different forms of 6-chloro-2-ethyl-n-(4-(4-(4(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide
CN116178277A (zh) 氯比普兰甲磺酸盐晶型及其制备方法
KR20170036288A (ko) 시타글립틴의 신규염 및 이의 제조방법
CN116178275A (zh) 氯比普兰氢溴酸盐晶型及其制备方法
EP1768969B1 (en) Crystalline mycophenolate sodium
CN116178276A (zh) 氯比普兰盐酸盐晶型及其制备方法
CN120230109A (zh) 一种亚砜亚胺类化合物的酸式盐的晶型及其制备方法和用途
CN114040908A (zh) 一种凝血因子XIa抑制剂的晶型及其制备方法
HK40062038B (en) Method for synthesizing furoimidazopyridine compound, polymorphic substance and polymorphic substance of salt